anti mouse cd105 pe cy7 Search Results


anti endoglin  (Developmental Studies Hybridoma Bank)
94
Developmental Studies Hybridoma Bank anti endoglin
Anti Endoglin, supplied by Developmental Studies Hybridoma Bank, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti endoglin/product/Developmental Studies Hybridoma Bank
Average 94 stars, based on 1 article reviews
anti endoglin - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
cd105 antibody, anti-mouse  (Miltenyi Biotec)
94
Miltenyi Biotec cd105 antibody, anti-mouse
Cd105 Antibody, Anti Mouse, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd105 antibody, anti-mouse/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
cd105 antibody, anti-mouse - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
mouse anti human cd105 antibody  (Cell Signaling Technology Inc)
94
Cell Signaling Technology Inc mouse anti human cd105 antibody
Figure 4. Phenotypic plasticity of mesenchymal marker expression (A) Flow cytometry analysis of PDPN and <t>CD105</t> in purified and in-vitro-cultured CD105pos and CD105neg pancreatic fibroblasts (PaFs) after 1 and 7 weeks. Plots are representative of n = 4 experiments. Relative frequencies shown in relevant quadrants. (B) Normalized Eng mRNA expression in purified CD105pos (n = 4) and CD105neg PaFs (n = 4) treated with control (top) or KPC PDA conditioned medium (bottom). Data displayed as mean ± SD. (C) Representative flow cytometry analysis (n = 4) of CD105 on GFPposCD105pos and GFPposCD105neg PaFs in mono- or co-culture with RFPpos KPC PDA tu- mor cells. (D) Representative flow cytometry analysis (n = 3) of CD105 in isolated CD105pos and CD105neg human PaFs after >3 weeks of in vitro culture. (E and F) MC analysis of primary PaFs treated with the indicated ligands for 3 days. Representative plots displaying relative frequencies of CD105pos and CD105neg PaFs. (G and H) Heatmap of median marker intensity (MMI) displayed as column Z scores for each phenotypic marker on CD105pos (G) and CD105neg (H) PaFs after 3 days of treatment as indicated. Boxplots show MMI with upper and lower boundary of the interquartile range and whiskers denoting maximum and minimum values minus outliers, across all conditions. (I and J) Representative flow cytometry analysis (n = 3) of CD105pos (I) and CD105neg (J) PaFs with IFN-g, IFN-g + KPC PDA conditioned medium, or IFN-g + TGF- b1 treatment. Samples are compared using unpaired t tests (B) (top and bottom). ns, not significant; *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S5 and Table S4.
Mouse Anti Human Cd105 Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti human cd105 antibody/product/Cell Signaling Technology Inc
Average 94 stars, based on 1 article reviews
mouse anti human cd105 antibody - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
anti-cd105 allophyocyanin (apc  (Becton Dickinson)
90
Becton Dickinson anti-cd105 allophyocyanin (apc
Figure 4. Phenotypic plasticity of mesenchymal marker expression (A) Flow cytometry analysis of PDPN and <t>CD105</t> in purified and in-vitro-cultured CD105pos and CD105neg pancreatic fibroblasts (PaFs) after 1 and 7 weeks. Plots are representative of n = 4 experiments. Relative frequencies shown in relevant quadrants. (B) Normalized Eng mRNA expression in purified CD105pos (n = 4) and CD105neg PaFs (n = 4) treated with control (top) or KPC PDA conditioned medium (bottom). Data displayed as mean ± SD. (C) Representative flow cytometry analysis (n = 4) of CD105 on GFPposCD105pos and GFPposCD105neg PaFs in mono- or co-culture with RFPpos KPC PDA tu- mor cells. (D) Representative flow cytometry analysis (n = 3) of CD105 in isolated CD105pos and CD105neg human PaFs after >3 weeks of in vitro culture. (E and F) MC analysis of primary PaFs treated with the indicated ligands for 3 days. Representative plots displaying relative frequencies of CD105pos and CD105neg PaFs. (G and H) Heatmap of median marker intensity (MMI) displayed as column Z scores for each phenotypic marker on CD105pos (G) and CD105neg (H) PaFs after 3 days of treatment as indicated. Boxplots show MMI with upper and lower boundary of the interquartile range and whiskers denoting maximum and minimum values minus outliers, across all conditions. (I and J) Representative flow cytometry analysis (n = 3) of CD105pos (I) and CD105neg (J) PaFs with IFN-g, IFN-g + KPC PDA conditioned medium, or IFN-g + TGF- b1 treatment. Samples are compared using unpaired t tests (B) (top and bottom). ns, not significant; *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S5 and Table S4.
Anti Cd105 Allophyocyanin (Apc, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-cd105 allophyocyanin (apc/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
anti-cd105 allophyocyanin (apc - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
anti mouse endoglin cd105  (R&D Systems)
93
R&D Systems anti mouse endoglin cd105
Figure 4. Phenotypic plasticity of mesenchymal marker expression (A) Flow cytometry analysis of PDPN and <t>CD105</t> in purified and in-vitro-cultured CD105pos and CD105neg pancreatic fibroblasts (PaFs) after 1 and 7 weeks. Plots are representative of n = 4 experiments. Relative frequencies shown in relevant quadrants. (B) Normalized Eng mRNA expression in purified CD105pos (n = 4) and CD105neg PaFs (n = 4) treated with control (top) or KPC PDA conditioned medium (bottom). Data displayed as mean ± SD. (C) Representative flow cytometry analysis (n = 4) of CD105 on GFPposCD105pos and GFPposCD105neg PaFs in mono- or co-culture with RFPpos KPC PDA tu- mor cells. (D) Representative flow cytometry analysis (n = 3) of CD105 in isolated CD105pos and CD105neg human PaFs after >3 weeks of in vitro culture. (E and F) MC analysis of primary PaFs treated with the indicated ligands for 3 days. Representative plots displaying relative frequencies of CD105pos and CD105neg PaFs. (G and H) Heatmap of median marker intensity (MMI) displayed as column Z scores for each phenotypic marker on CD105pos (G) and CD105neg (H) PaFs after 3 days of treatment as indicated. Boxplots show MMI with upper and lower boundary of the interquartile range and whiskers denoting maximum and minimum values minus outliers, across all conditions. (I and J) Representative flow cytometry analysis (n = 3) of CD105pos (I) and CD105neg (J) PaFs with IFN-g, IFN-g + KPC PDA conditioned medium, or IFN-g + TGF- b1 treatment. Samples are compared using unpaired t tests (B) (top and bottom). ns, not significant; *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S5 and Table S4.
Anti Mouse Endoglin Cd105, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti mouse endoglin cd105/product/R&D Systems
Average 93 stars, based on 1 article reviews
anti mouse endoglin cd105 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
anti cd105  (OriGene)
99
OriGene anti cd105
Figure 4. Phenotypic plasticity of mesenchymal marker expression (A) Flow cytometry analysis of PDPN and <t>CD105</t> in purified and in-vitro-cultured CD105pos and CD105neg pancreatic fibroblasts (PaFs) after 1 and 7 weeks. Plots are representative of n = 4 experiments. Relative frequencies shown in relevant quadrants. (B) Normalized Eng mRNA expression in purified CD105pos (n = 4) and CD105neg PaFs (n = 4) treated with control (top) or KPC PDA conditioned medium (bottom). Data displayed as mean ± SD. (C) Representative flow cytometry analysis (n = 4) of CD105 on GFPposCD105pos and GFPposCD105neg PaFs in mono- or co-culture with RFPpos KPC PDA tu- mor cells. (D) Representative flow cytometry analysis (n = 3) of CD105 in isolated CD105pos and CD105neg human PaFs after >3 weeks of in vitro culture. (E and F) MC analysis of primary PaFs treated with the indicated ligands for 3 days. Representative plots displaying relative frequencies of CD105pos and CD105neg PaFs. (G and H) Heatmap of median marker intensity (MMI) displayed as column Z scores for each phenotypic marker on CD105pos (G) and CD105neg (H) PaFs after 3 days of treatment as indicated. Boxplots show MMI with upper and lower boundary of the interquartile range and whiskers denoting maximum and minimum values minus outliers, across all conditions. (I and J) Representative flow cytometry analysis (n = 3) of CD105pos (I) and CD105neg (J) PaFs with IFN-g, IFN-g + KPC PDA conditioned medium, or IFN-g + TGF- b1 treatment. Samples are compared using unpaired t tests (B) (top and bottom). ns, not significant; *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S5 and Table S4.
Anti Cd105, supplied by OriGene, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cd105/product/OriGene
Average 99 stars, based on 1 article reviews
anti cd105 - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
anti-mouse cd144  (Becton Dickinson)
90
Becton Dickinson anti-mouse cd144
Figure 4. Phenotypic plasticity of mesenchymal marker expression (A) Flow cytometry analysis of PDPN and <t>CD105</t> in purified and in-vitro-cultured CD105pos and CD105neg pancreatic fibroblasts (PaFs) after 1 and 7 weeks. Plots are representative of n = 4 experiments. Relative frequencies shown in relevant quadrants. (B) Normalized Eng mRNA expression in purified CD105pos (n = 4) and CD105neg PaFs (n = 4) treated with control (top) or KPC PDA conditioned medium (bottom). Data displayed as mean ± SD. (C) Representative flow cytometry analysis (n = 4) of CD105 on GFPposCD105pos and GFPposCD105neg PaFs in mono- or co-culture with RFPpos KPC PDA tu- mor cells. (D) Representative flow cytometry analysis (n = 3) of CD105 in isolated CD105pos and CD105neg human PaFs after >3 weeks of in vitro culture. (E and F) MC analysis of primary PaFs treated with the indicated ligands for 3 days. Representative plots displaying relative frequencies of CD105pos and CD105neg PaFs. (G and H) Heatmap of median marker intensity (MMI) displayed as column Z scores for each phenotypic marker on CD105pos (G) and CD105neg (H) PaFs after 3 days of treatment as indicated. Boxplots show MMI with upper and lower boundary of the interquartile range and whiskers denoting maximum and minimum values minus outliers, across all conditions. (I and J) Representative flow cytometry analysis (n = 3) of CD105pos (I) and CD105neg (J) PaFs with IFN-g, IFN-g + KPC PDA conditioned medium, or IFN-g + TGF- b1 treatment. Samples are compared using unpaired t tests (B) (top and bottom). ns, not significant; *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S5 and Table S4.
Anti Mouse Cd144, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-mouse cd144/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
anti-mouse cd144 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
apc-conjugated mouse anti-human cd105  (Thermo Fisher)
90
Thermo Fisher apc-conjugated mouse anti-human cd105
Figure 4. Phenotypic plasticity of mesenchymal marker expression (A) Flow cytometry analysis of PDPN and <t>CD105</t> in purified and in-vitro-cultured CD105pos and CD105neg pancreatic fibroblasts (PaFs) after 1 and 7 weeks. Plots are representative of n = 4 experiments. Relative frequencies shown in relevant quadrants. (B) Normalized Eng mRNA expression in purified CD105pos (n = 4) and CD105neg PaFs (n = 4) treated with control (top) or KPC PDA conditioned medium (bottom). Data displayed as mean ± SD. (C) Representative flow cytometry analysis (n = 4) of CD105 on GFPposCD105pos and GFPposCD105neg PaFs in mono- or co-culture with RFPpos KPC PDA tu- mor cells. (D) Representative flow cytometry analysis (n = 3) of CD105 in isolated CD105pos and CD105neg human PaFs after >3 weeks of in vitro culture. (E and F) MC analysis of primary PaFs treated with the indicated ligands for 3 days. Representative plots displaying relative frequencies of CD105pos and CD105neg PaFs. (G and H) Heatmap of median marker intensity (MMI) displayed as column Z scores for each phenotypic marker on CD105pos (G) and CD105neg (H) PaFs after 3 days of treatment as indicated. Boxplots show MMI with upper and lower boundary of the interquartile range and whiskers denoting maximum and minimum values minus outliers, across all conditions. (I and J) Representative flow cytometry analysis (n = 3) of CD105pos (I) and CD105neg (J) PaFs with IFN-g, IFN-g + KPC PDA conditioned medium, or IFN-g + TGF- b1 treatment. Samples are compared using unpaired t tests (B) (top and bottom). ns, not significant; *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S5 and Table S4.
Apc Conjugated Mouse Anti Human Cd105, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/apc-conjugated mouse anti-human cd105/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
apc-conjugated mouse anti-human cd105 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
goat gh antiserum  (Santa Cruz Biotechnology)
96
Santa Cruz Biotechnology goat gh antiserum
Figure 4. Phenotypic plasticity of mesenchymal marker expression (A) Flow cytometry analysis of PDPN and <t>CD105</t> in purified and in-vitro-cultured CD105pos and CD105neg pancreatic fibroblasts (PaFs) after 1 and 7 weeks. Plots are representative of n = 4 experiments. Relative frequencies shown in relevant quadrants. (B) Normalized Eng mRNA expression in purified CD105pos (n = 4) and CD105neg PaFs (n = 4) treated with control (top) or KPC PDA conditioned medium (bottom). Data displayed as mean ± SD. (C) Representative flow cytometry analysis (n = 4) of CD105 on GFPposCD105pos and GFPposCD105neg PaFs in mono- or co-culture with RFPpos KPC PDA tu- mor cells. (D) Representative flow cytometry analysis (n = 3) of CD105 in isolated CD105pos and CD105neg human PaFs after >3 weeks of in vitro culture. (E and F) MC analysis of primary PaFs treated with the indicated ligands for 3 days. Representative plots displaying relative frequencies of CD105pos and CD105neg PaFs. (G and H) Heatmap of median marker intensity (MMI) displayed as column Z scores for each phenotypic marker on CD105pos (G) and CD105neg (H) PaFs after 3 days of treatment as indicated. Boxplots show MMI with upper and lower boundary of the interquartile range and whiskers denoting maximum and minimum values minus outliers, across all conditions. (I and J) Representative flow cytometry analysis (n = 3) of CD105pos (I) and CD105neg (J) PaFs with IFN-g, IFN-g + KPC PDA conditioned medium, or IFN-g + TGF- b1 treatment. Samples are compared using unpaired t tests (B) (top and bottom). ns, not significant; *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S5 and Table S4.
Goat Gh Antiserum, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/goat gh antiserum/product/Santa Cruz Biotechnology
Average 96 stars, based on 1 article reviews
goat gh antiserum - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
anti-cd105  (Bio-Rad)
90
Bio-Rad anti-cd105
Figure 4. Phenotypic plasticity of mesenchymal marker expression (A) Flow cytometry analysis of PDPN and <t>CD105</t> in purified and in-vitro-cultured CD105pos and CD105neg pancreatic fibroblasts (PaFs) after 1 and 7 weeks. Plots are representative of n = 4 experiments. Relative frequencies shown in relevant quadrants. (B) Normalized Eng mRNA expression in purified CD105pos (n = 4) and CD105neg PaFs (n = 4) treated with control (top) or KPC PDA conditioned medium (bottom). Data displayed as mean ± SD. (C) Representative flow cytometry analysis (n = 4) of CD105 on GFPposCD105pos and GFPposCD105neg PaFs in mono- or co-culture with RFPpos KPC PDA tu- mor cells. (D) Representative flow cytometry analysis (n = 3) of CD105 in isolated CD105pos and CD105neg human PaFs after >3 weeks of in vitro culture. (E and F) MC analysis of primary PaFs treated with the indicated ligands for 3 days. Representative plots displaying relative frequencies of CD105pos and CD105neg PaFs. (G and H) Heatmap of median marker intensity (MMI) displayed as column Z scores for each phenotypic marker on CD105pos (G) and CD105neg (H) PaFs after 3 days of treatment as indicated. Boxplots show MMI with upper and lower boundary of the interquartile range and whiskers denoting maximum and minimum values minus outliers, across all conditions. (I and J) Representative flow cytometry analysis (n = 3) of CD105pos (I) and CD105neg (J) PaFs with IFN-g, IFN-g + KPC PDA conditioned medium, or IFN-g + TGF- b1 treatment. Samples are compared using unpaired t tests (B) (top and bottom). ns, not significant; *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S5 and Table S4.
Anti Cd105, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-cd105/product/Bio-Rad
Average 90 stars, based on 1 article reviews
anti-cd105 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
cd105  (Miltenyi Biotec)
94
Miltenyi Biotec cd105
Figure 4. Phenotypic plasticity of mesenchymal marker expression (A) Flow cytometry analysis of PDPN and <t>CD105</t> in purified and in-vitro-cultured CD105pos and CD105neg pancreatic fibroblasts (PaFs) after 1 and 7 weeks. Plots are representative of n = 4 experiments. Relative frequencies shown in relevant quadrants. (B) Normalized Eng mRNA expression in purified CD105pos (n = 4) and CD105neg PaFs (n = 4) treated with control (top) or KPC PDA conditioned medium (bottom). Data displayed as mean ± SD. (C) Representative flow cytometry analysis (n = 4) of CD105 on GFPposCD105pos and GFPposCD105neg PaFs in mono- or co-culture with RFPpos KPC PDA tu- mor cells. (D) Representative flow cytometry analysis (n = 3) of CD105 in isolated CD105pos and CD105neg human PaFs after >3 weeks of in vitro culture. (E and F) MC analysis of primary PaFs treated with the indicated ligands for 3 days. Representative plots displaying relative frequencies of CD105pos and CD105neg PaFs. (G and H) Heatmap of median marker intensity (MMI) displayed as column Z scores for each phenotypic marker on CD105pos (G) and CD105neg (H) PaFs after 3 days of treatment as indicated. Boxplots show MMI with upper and lower boundary of the interquartile range and whiskers denoting maximum and minimum values minus outliers, across all conditions. (I and J) Representative flow cytometry analysis (n = 3) of CD105pos (I) and CD105neg (J) PaFs with IFN-g, IFN-g + KPC PDA conditioned medium, or IFN-g + TGF- b1 treatment. Samples are compared using unpaired t tests (B) (top and bottom). ns, not significant; *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S5 and Table S4.
Cd105, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd105/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
cd105 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
primary anti-human cd105-pe  (Miltenyi Biotec)
95
Miltenyi Biotec primary anti-human cd105-pe
Figure 4. Phenotypic plasticity of mesenchymal marker expression (A) Flow cytometry analysis of PDPN and <t>CD105</t> in purified and in-vitro-cultured CD105pos and CD105neg pancreatic fibroblasts (PaFs) after 1 and 7 weeks. Plots are representative of n = 4 experiments. Relative frequencies shown in relevant quadrants. (B) Normalized Eng mRNA expression in purified CD105pos (n = 4) and CD105neg PaFs (n = 4) treated with control (top) or KPC PDA conditioned medium (bottom). Data displayed as mean ± SD. (C) Representative flow cytometry analysis (n = 4) of CD105 on GFPposCD105pos and GFPposCD105neg PaFs in mono- or co-culture with RFPpos KPC PDA tu- mor cells. (D) Representative flow cytometry analysis (n = 3) of CD105 in isolated CD105pos and CD105neg human PaFs after >3 weeks of in vitro culture. (E and F) MC analysis of primary PaFs treated with the indicated ligands for 3 days. Representative plots displaying relative frequencies of CD105pos and CD105neg PaFs. (G and H) Heatmap of median marker intensity (MMI) displayed as column Z scores for each phenotypic marker on CD105pos (G) and CD105neg (H) PaFs after 3 days of treatment as indicated. Boxplots show MMI with upper and lower boundary of the interquartile range and whiskers denoting maximum and minimum values minus outliers, across all conditions. (I and J) Representative flow cytometry analysis (n = 3) of CD105pos (I) and CD105neg (J) PaFs with IFN-g, IFN-g + KPC PDA conditioned medium, or IFN-g + TGF- b1 treatment. Samples are compared using unpaired t tests (B) (top and bottom). ns, not significant; *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S5 and Table S4.
Primary Anti Human Cd105 Pe, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/primary anti-human cd105-pe/product/Miltenyi Biotec
Average 95 stars, based on 1 article reviews
primary anti-human cd105-pe - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

Image Search Results


Figure 4. Phenotypic plasticity of mesenchymal marker expression (A) Flow cytometry analysis of PDPN and CD105 in purified and in-vitro-cultured CD105pos and CD105neg pancreatic fibroblasts (PaFs) after 1 and 7 weeks. Plots are representative of n = 4 experiments. Relative frequencies shown in relevant quadrants. (B) Normalized Eng mRNA expression in purified CD105pos (n = 4) and CD105neg PaFs (n = 4) treated with control (top) or KPC PDA conditioned medium (bottom). Data displayed as mean ± SD. (C) Representative flow cytometry analysis (n = 4) of CD105 on GFPposCD105pos and GFPposCD105neg PaFs in mono- or co-culture with RFPpos KPC PDA tu- mor cells. (D) Representative flow cytometry analysis (n = 3) of CD105 in isolated CD105pos and CD105neg human PaFs after >3 weeks of in vitro culture. (E and F) MC analysis of primary PaFs treated with the indicated ligands for 3 days. Representative plots displaying relative frequencies of CD105pos and CD105neg PaFs. (G and H) Heatmap of median marker intensity (MMI) displayed as column Z scores for each phenotypic marker on CD105pos (G) and CD105neg (H) PaFs after 3 days of treatment as indicated. Boxplots show MMI with upper and lower boundary of the interquartile range and whiskers denoting maximum and minimum values minus outliers, across all conditions. (I and J) Representative flow cytometry analysis (n = 3) of CD105pos (I) and CD105neg (J) PaFs with IFN-g, IFN-g + KPC PDA conditioned medium, or IFN-g + TGF- b1 treatment. Samples are compared using unpaired t tests (B) (top and bottom). ns, not significant; *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S5 and Table S4.

Journal: Cancer cell

Article Title: Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity.

doi: 10.1016/j.ccell.2021.06.017

Figure Lengend Snippet: Figure 4. Phenotypic plasticity of mesenchymal marker expression (A) Flow cytometry analysis of PDPN and CD105 in purified and in-vitro-cultured CD105pos and CD105neg pancreatic fibroblasts (PaFs) after 1 and 7 weeks. Plots are representative of n = 4 experiments. Relative frequencies shown in relevant quadrants. (B) Normalized Eng mRNA expression in purified CD105pos (n = 4) and CD105neg PaFs (n = 4) treated with control (top) or KPC PDA conditioned medium (bottom). Data displayed as mean ± SD. (C) Representative flow cytometry analysis (n = 4) of CD105 on GFPposCD105pos and GFPposCD105neg PaFs in mono- or co-culture with RFPpos KPC PDA tu- mor cells. (D) Representative flow cytometry analysis (n = 3) of CD105 in isolated CD105pos and CD105neg human PaFs after >3 weeks of in vitro culture. (E and F) MC analysis of primary PaFs treated with the indicated ligands for 3 days. Representative plots displaying relative frequencies of CD105pos and CD105neg PaFs. (G and H) Heatmap of median marker intensity (MMI) displayed as column Z scores for each phenotypic marker on CD105pos (G) and CD105neg (H) PaFs after 3 days of treatment as indicated. Boxplots show MMI with upper and lower boundary of the interquartile range and whiskers denoting maximum and minimum values minus outliers, across all conditions. (I and J) Representative flow cytometry analysis (n = 3) of CD105pos (I) and CD105neg (J) PaFs with IFN-g, IFN-g + KPC PDA conditioned medium, or IFN-g + TGF- b1 treatment. Samples are compared using unpaired t tests (B) (top and bottom). ns, not significant; *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S5 and Table S4.

Article Snippet: The first staining round used mouse anti-human CD105 antibody (CST clone 3A9) at 1/200 and TSA570 (FP1488001KT).

Techniques: Marker, Expressing, Flow Cytometry, In Vitro, Cell Culture, Control, Cytometry, Co-Culture Assay, Isolation